ClinicalTrials.Veeva
Menu

Find clinical trials for Acute Myeloid Leukemia (AML) in New York, NY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Acute Myeloid Leukemia
Leukemia
Myeloid Leukemia
Myelodysplastic Syndromes
Preleukemia
Syndrome
Cancer

Acute Myeloid Leukemia (AML) trials near New York, NY, USA:

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute...

Active, not recruiting
Leukemia, Acute Myeloid (AML)
Drug: LoDAC (Low Dose Cytarabine)
Drug: MEC (Mitoxantrone, Etoposide, Cytarabine)

Phase 3

Astellas
Astellas

New York, New York, United States and 125 other locations

The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Cancer
Other: Best Supportive Care (BSC)
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

New York, New York, United States and 164 other locations

Locations recently updated

Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children ...

Enrolling
Acute Myeloid Leukemia
Drug: ABBV-787

Phase 1

AbbVie
AbbVie

New York, New York, United States and 17 other locations

CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid...

Enrolling
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome (MDS)
Drug: CLN-049

Phase 1

Cullinan Oncology Inc.

New York, New York, United States and 6 other locations

allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid...

Active, not recruiting
AML
Acute Myelogenous Leukemia
Drug: Conventional Care
Drug: Iomab-B

Phase 3

Actinium Pharmaceuticals
Actinium Pharmaceuticals

New York, New York, United States and 23 other locations

People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML hav...

Enrolling
Acute Myeloid Leukemia (AML)
FLT3-mutated Acute Myeloid Leukemia
Drug: Venetoclax
Drug: Gilteritinib

Phase 1, Phase 2

Astellas
Astellas

New York, New York, United States and 18 other locations

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of JNJ-75276617 in combination with AML directed ...

Enrolling
Leukemia, Myeloid, Acute
Drug: Azacitidine (AZA)
Drug: Cytarabine

Phase 1

Janssen (J&J Innovative Medicine)

New York, New York, United States and 30 other locations

Antisense Oligodeoxynucleotide) in patients with refractory/relapsed AML. The study is designed to assess the safety profile, identify DLTs,...

Enrolling
Acute Myeloid Leukemia Refractory
Acute Myeloid Leukemia, in Relapse
Drug: Decitabine (in combination with BP1002)
Drug: BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide

Phase 1

Bio-Path

New York, New York, United States and 3 other locations

A Phase 1/2 dose escalation study of BCL-2 Inhibitor ZN-d5 and the Wee1 Inhibitor ZN-c3 in Subjects with Acute Myeloid Leukemia...

Enrolling
Acute Myeloid Leukemia (AML)
Drug: ZN-c3
Drug: ZN-d5 ZN-c3

Phase 1, Phase 2

K-Group Alpha

New York, New York, United States and 12 other locations

a safe and effective treatment for people with relapsed/refractory AML with FLT3/IDH1 or FLT3/IDH2 gene mutations. The researchers will also...

Enrolling
Acute Myeloid Leukemia (AML)
Drug: Ivosidenib
Drug: Gilteritinib

Phase 1

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

New York, New York, United States and 6 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems